CLAIMS

What is claimed is:

- 1. A method for increasing survival of oligodendrocytes, comprising administering an effective amount of a deprenyl compound to a patient such that survival of oligodendrocytes is increased.
- 2. The method of claim 1, wherein the deprenyl compound is represented by the structure:

in which

5

15

20

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R₂ is hydrogen or alkyl;

 R_3 is a single bond, alkylene, or $-(CH_2)_n-X-(CH_2)_m$;

in which X is O, S, or N-methyl; m is 1 or 2; and n is 0,1, or 2;

R₄ is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R5 is alkylene, alkenylene, alkynylene and alkoxylene; and

R6 is C3-C6 cycloalkyl or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

- 3. The method of claim 2, wherein R₁ is a group that can be removed *in vivo*.
- 4. The method of claim 2, wherein R₁ is hydrogen.
- 5. The method of claim 2, wherein R_1 is alkyl.
- 6. The method of claim 2, wherein R₁ is methyl.
- 25 7. The method of claim 2, wherein R₂ is methyl.
 - 8. The method of claim 2, wherein R₃ is methylene.
 - 9. The method of claim 2, wherein R₄ is aryl.
 - 10. The method of claim 2, wherein R₄ is phenyl.
 - 11. The method of claim 2, wherein R₅ is methylene.
- 30 12. The method of claim 2, wherein R_6 is

—C≡CH

13. The method of claim 2, wherein the deprenyl compound is represented by the structure:

$$R_4$$
— R_3 — CH — N
 R_2
 CH_2 — C = CH

in which

5

15

20

25

30

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R₂ is hydrogen or alkyl;

R₃ is a bond or methylene; and

R4 is aryl or aralkyl; or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

14. The method of claim 2, wherein the deprenyl compound is represented by the structure:

$$R_4$$
— R_3 — CH — R_2 R_5 — C = CH

in which

R₂ is hydrogen or alkyl;

R₃ is a bond or methylene; and

R₄ is aryl or aralkyl; or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R₅ is alkylene, alkenylene, alkynylene and alkoxylene; and pharmaceutically acceptable salts thereof.

15. The method of claim 2, wherein the deprenyl compound is represented by the structure:

$$CH_2$$
- CH - R_1
 CH_3 CH_2 - C = CH

in which

R₁ is hydrogen, alkyl, alkenyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

A is a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxyl, cyano, nitro, amino, carboxyl, -CF3, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

- 16. The method of claim 1, wherein said patient is a human.
- 17. The method of claim 1, wherein said deprenyl compound is (-)-desmethyldeprenyl.
- 18. A method for inhibiting Multiple Sclerosis, comprising administering to a patient an effective amount of a deprenyl compound such that Multiple Sclerosis is inhibited.
- 5 19. The method of claim 18, wherein said deprenyl compound is (-)-desmethyldeprenyl.
 - 20. The method of claim 18, wherein said patient is a human.
 - 21. A method for increasing oligodendrocyte survival *in vitro*, comprising contacting oligodendrocytes with an effective amount of a deprenyl compound such that oligodendrocyte survival is increased.
- 10 22. A method for increasing oligodendrocyte survival in a patient, comprising contacting an oligodendrocyte with a deprenyl compound such that oligodendrocyte survival increases.
 - 23. The method of claim 22, wherein said patient is a human.
 - 24. The method of claim 23, wherein the deprenyl compound is (-)-desmethyldeprenyl.
- 25. The method of claim 24, wherein the (-)-desmethyldeprenyl is administered transdermally to the patient.